血清微小RNA作为早期乳癌诊断标志物的价值  

THE VALUE OF SERUM MICRORNAS AS BIOMARKERS FOR EARLY DIAGNOSIS OF BREAST CANCER

作　　者：程晓鸥 张金玉[1] 葛银林[1] 郑征[1] 李振凤[1] 侯琳[1] 

机构地区：[1]青岛大学医学院生物化学与分子生物学教研室,山东青岛266021

出　　处：《齐鲁医学杂志》2014年第5期407-410,共4页Medical Journal of Qilu

基　　金：青岛市科技局资助项目(08-2-1-4-nsh);山东省自然科学基金资助项目(ZR2012HM089)

摘　　要：目的探讨血清5种微小RNA(miRNA)在乳癌早期诊断中作为生物标记物的价值。方法根据生物信息学数据库miRWalk的预测,选定5种与乳癌相关的miRNA(包括miR-31、miR-107、miR-155、miR-200c及miR-205)。采用实时荧光定量PCR检测5种miRNA在42例健康女性、66例乳癌病人中的相对表达量,根据受试者工作特征曲线(ROC曲线)下面积分析诊断乳癌的特异度和灵敏度。结果血清中miR-31、miR-107和miR-200c联合检测诊断乳癌的灵敏度为78.6%,特异度为88.7%。结论血清中miR-31、miR-107和miR-200c的组合有可能成为乳癌早期诊断的新指标。Objective To assess the value of five serum microRNAs（miRNA）as biomarkers for early diagnosis of breast cancer. Methods According to bioinformatics database miRWalk prediction,five breast-cancer-related miRNAs（miR-31,miR-107,miR-155,miR-200 cand miR-205）were selected.The expressions of the five miRNAs in serum samples of 42 normal controls and 66 breast cancer patients were detected by real-time quantitative PCR.Specificity and sensitivity were analyzed by the areas under the receiver operating characteristic（ROC）curves of these miRNAs. Results The sensitivity and specificity of combined miR-31,miR-107 and miR-200 cfor breast cancer diagnosis were 78.6%and 88.7%,respectively. Conclusion The combination of serum miR-31,miR-107 and miR-200 cmay become a new marker for early diagnosis of breast cancer.

关 键 词：微RNAS 乳房肿瘤 生物学标记 早期诊断 

分 类 号：R737.9[医药卫生—肿瘤]